Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 102

    1.

    Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function.

    Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS; the Type 1 Diabetes TrialNet Anti-CD20 Study Group.

    N Engl J Med. 2009 Nov 26;361(22):2143-2152.PMID: 19940299 [PubMed - as supplied by publisher]

    2.

    Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T cells of T1D subjects.

    Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum C, Buckner JH.

    Diabetes. 2009 Oct 29. [Epub ahead of print]PMID: 19875613 [PubMed - as supplied by publisher]Related articles

    3.

    Preservation of beta-cell function in autoantibody-positive youth with diabetes.

    Greenbaum CJ, Anderson AM, Dolan LM, Mayer-Davis EJ, Dabelea D, Imperatore G, Marcovina S, Pihoker C; SEARCH Study Group.

    Diabetes Care. 2009 Oct;32(10):1839-44. Epub 2009 Jul 8.PMID: 19587365 [PubMed - in process]Related articles

    4.

    Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1.

    Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum CJ, Cowie CC, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

    Diabetes Care. 2009 Sep;32(9):1603-7. Epub 2009 Jun 1.PMID: 19487644 [PubMed - indexed for MEDLINE]Related articles

    5.

    Changes in autoreactive T cell avidity during type 1 diabetes development.

    Standifer NE, Burwell EA, Gersuk VH, Greenbaum CJ, Nepom GT.

    Clin Immunol. 2009 Sep;132(3):312-20. Epub 2009 May 23.PMID: 19482555 [PubMed - indexed for MEDLINE]Related articles

    6.

    Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

    Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group.

    Clin Immunol. 2009 Aug;132(2):166-73. Epub 2009 May 14.PMID: 19443276 [PubMed - indexed for MEDLINE]Related articles

    7.

    The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis.

    Ma X, Becker D, Arena VC, Vicini P, Greenbaum C.

    J Clin Endocrinol Metab. 2009 Jul;94(7):2446-51. Epub 2009 Apr 28.PMID: 19401372 [PubMed - indexed for MEDLINE]Related articles

    8.

    Omental Roll-Up: A Technique for Islet Engraftment in a Large Animal Model.

    Hefty TR, Kuhr CS, Chong KT, Guinee DG, Wang W, Reems JA, Greenbaum CJ.

    J Surg Res. 2008 Dec 13. [Epub ahead of print]PMID: 19394649 [PubMed - as supplied by publisher]Related articles

    9.

    Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects.

    Long SA, Walker MR, Rieck M, James E, Kwok WW, Sanda S, Pihoker C, Greenbaum C, Nepom GT, Buckner JH.

    Eur J Immunol. 2009 Feb;39(2):612-20.PMID: 19180473 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Divorce is a part of my life... resilience, survival, and vulnerability: young adults' perception of the implications of parental divorce.

    Eldar-Avidan D, Haj-Yahia MM, Greenbaum CW.

    J Marital Fam Ther. 2009 Jan;35(1):30-46.PMID: 19161582 [PubMed - indexed for MEDLINE]Related articles

    11.

    Type 1 Diabetes TrialNet--an international collaborative clinical trials network.

    Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L; Type 1 Diabetes TrialNet Study Group.

    Ann N Y Acad Sci. 2008 Dec;1150:14-24.PMID: 19120262 [PubMed - indexed for MEDLINE]Related articles

    12.

    The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.

    Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH.

    J Immunol. 2008 Nov 15;181(10):7350-5.PMID: 18981158 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Type 1 diabetes mellitus: primary, secondary, and tertiary prevention.

    Bollyky J, Sanda S, Greenbaum CJ.

    Mt Sinai J Med. 2008 Aug;75(4):385-97. Review.PMID: 18729155 [PubMed - indexed for MEDLINE]Related articles

    14.

    Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.

    Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group.

    Diabetes Care. 2008 Oct;31(10):1966-71. Epub 2008 Jul 15.PMID: 18628574 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Standardization of C-peptide measurements.

    Little RR, Rohlfing CL, Tennill AL, Madsen RW, Polonsky KS, Myers GL, Greenbaum CJ, Palmer JP, Rogatsky E, Stein DT.

    Clin Chem. 2008 Jun;54(6):1023-6. Epub 2008 Apr 17.PMID: 18420730 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope.

    Yang J, Danke N, Roti M, Huston L, Greenbaum C, Pihoker C, James E, Kwok WW.

    J Autoimmun. 2008 Aug;31(1):30-41. Epub 2008 Apr 2.PMID: 18385016 [PubMed - indexed for MEDLINE]Related articles

    17.

    Use of oral glucose minimal model-derived index of insulin sensitivity in subjects with early type 1 diabetes mellitus.

    Krudys KM, Greenbaum CJ, Pihoker C, Vicini P.

    Metabolism. 2008 Apr;57(4):445-7.PMID: 18328342 [PubMed - indexed for MEDLINE]Related articles

    18.

    A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.

    Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

    Diabetes Care. 2008 Mar;31(3):528-33. Epub 2007 Nov 13.PMID: 18000175 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes.

    Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH.

    J Immunol. 2007 Oct 1;179(7):4704-10.PMID: 17878369 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still out.

    Bollyky J, Greenbaum CJ.

    J Clin Endocrinol Metab. 2007 Aug;92(8):2879-81. No abstract available. PMID: 17682088 [PubMed - indexed for MEDLINE]Related articlesFree article

    21.

    Role of insulin resistance in predicting progression to type 1 diabetes.

    Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP; Diabetes Prevention Trial-Type 1 Study Group.

    Diabetes Care. 2007 Sep;30(9):2314-20. Epub 2007 May 29.PMID: 17536068 [PubMed - indexed for MEDLINE]Related articlesFree article

    22.

    International comparison of C-peptide measurements.

    Wiedmeyer HM, Polonsky KS, Myers GL, Little RR, Greenbaum CJ, Goldstein DE, Palmer JP.

    Clin Chem. 2007 Apr;53(4):784-7. Epub 2007 Mar 1.PMID: 17332147 [PubMed - indexed for MEDLINE]Related articlesFree article

    23.

    Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1.

    Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

    Diabetes Care. 2007 Jan;30(1):38-42.PMID: 17192330 [PubMed - indexed for MEDLINE]Related articlesFree article

    24.

    Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives.

    Standifer NE, Ouyang Q, Panagiotopoulos C, Verchere CB, Tan R, Greenbaum CJ, Pihoker C, Nepom GT.

    Diabetes. 2006 Nov;55(11):3061-7.PMID: 17065343 [PubMed - indexed for MEDLINE]Related articlesFree article

    25.

    Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.

    Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC.

    Diabetes. 2006 Sep;55(9):2588-94.PMID: 16936208 [PubMed - indexed for MEDLINE]Related articlesFree article

    27.

    Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.

    Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS.

    Diabetes Care. 2006 Mar;29(3):643-9.PMID: 16505520 [PubMed - indexed for MEDLINE]Related articlesFree article

    28.

    Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects.

    Yang J, Danke NA, Berger D, Reichstetter S, Reijonen H, Greenbaum C, Pihoker C, James EA, Kwok WW.

    J Immunol. 2006 Mar 1;176(5):2781-9.PMID: 16493034 [PubMed - indexed for MEDLINE]Related articlesFree article

    29.

    Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes.

    Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Palmer JP, Cuthbertson D, Eisenbarth GS, Krischer JP, Schatz D; Diabetes Prevention Trial Type 1 Study Group.

    J Clin Endocrinol Metab. 2006 May;91(5):1705-13. Epub 2006 Feb 7.PMID: 16464953 [PubMed - indexed for MEDLINE]Related articlesFree article

    30.

    Violence among Arab elementary school pupils in Israel.

    Marie-Alsana W, Haj-Yahia MM, Greenbaum CW.

    J Interpers Violence. 2006 Jan;21(1):58-88.PMID: 16399924 [PubMed - indexed for MEDLINE]Related articles

    31.

    Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.

    Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, Conlon PJ, Gottlieb PA.

    Scand J Immunol. 2006 Jan;63(1):59-69.PMID: 16398702 [PubMed - indexed for MEDLINE]Related articles

    32.

    Evaluation of leptin levels in subjects at risk for type 1 diabetes.

    Gilliam LK, Jensen RA, Yang P, Weigle DS, Greenbaum CJ, Pihoker C.

    J Autoimmun. 2006 Mar;26(2):133-7. Epub 2005 Dec 27.PMID: 16380228 [PubMed - indexed for MEDLINE]Related articles

    33.

    Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects.

    Danke NA, Yang J, Greenbaum C, Kwok WW.

    J Autoimmun. 2005 Dec;25(4):303-11. Epub 2005 Oct 24.PMID: 16249070 [PubMed - indexed for MEDLINE]Related articles

    34.

    Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes.

    Gilliam LK, Brooks-Worrell BM, Palmer JP, Greenbaum CJ, Pihoker C.

    J Autoimmun. 2005 Nov;25(3):244-50. Epub 2005 Oct 21.PMID: 16243484 [PubMed - indexed for MEDLINE]Related articles

    35.

    Latent autoimmune diabetes in adults (LADA) should be less latent.

    Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC.

    Diabetologia. 2005 Nov;48(11):2206-12. Epub 2005 Sep 29. Review.PMID: 16193284 [PubMed - indexed for MEDLINE]Related articles

    36.

    Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

    Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E.

    Diabetes Care. 2005 May;28(5):1068-76.PMID: 15855569 [PubMed - indexed for MEDLINE]Related articlesFree article

    37.

    Non-invasive imaging of beta cell mass: a quantitative analysis.

    Sweet IR, Cook DL, Lernmark A, Greenbaum CJ, Krohn KA.

    Diabetes Technol Ther. 2004 Oct;6(5):652-9.PMID: 15628819 [PubMed - indexed for MEDLINE]Related articles

    38.

    High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial--Type 1 Diabetes.

    Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D, Zeidler A, Orban T, Wasserfall C, Cuthbertson D, Krischer J; DPT-1 study group.

    Diabetologia. 2005 Jan;48(1):68-74. Epub 2004 Dec 16.PMID: 15602651 [PubMed - indexed for MEDLINE]Related articles

    39.

    Conformation-dependent GAD65 autoantibodies in diabetes.

    Luo D, Gilliam LK, Greenbaum C, Bekris L, Hampe CS, Daniels T, Richter W, Marcovina SM, Rolandsson O, Landin-Olsson M, Kockum I, Lernmark A.

    Diabetologia. 2004 Sep;47(9):1581-91. Epub 2004 Sep 8.PMID: 15365614 [PubMed - indexed for MEDLINE]Related articles

    40.

    Male sex increases the risk of autoimmunity but not type 1 diabetes.

    Krischer JP, Cuthbertson DD, Greenbaum C; Diabetes Prevention Trial-Type 1 Study Group.

    Diabetes Care. 2004 Aug;27(8):1985-90.PMID: 15277428 [PubMed - indexed for MEDLINE]Related articlesFree article

    41.

    GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes.

    Reijonen H, Mallone R, Heninger AK, Laughlin EM, Kochik SA, Falk B, Kwok WW, Greenbaum C, Nepom GT.

    Diabetes. 2004 Aug;53(8):1987-94.PMID: 15277377 [PubMed - indexed for MEDLINE]Related articlesFree article

    42.

    Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?

    Schatz D, Cuthbertson D, Atkinson M, Salzler MC, Winter W, Muir A, Silverstein J, Cook R, Maclaren N, She JX, Greenbaum C, Krischer J.

    Pediatr Diabetes. 2004 Jun;5(2):72-9.PMID: 15189492 [PubMed - indexed for MEDLINE]Related articles

    43.

    Autoimmunity to islet proteins in children diagnosed with new-onset diabetes.

    Brooks-Worrell BM, Greenbaum CJ, Palmer JP, Pihoker C.

    J Clin Endocrinol Metab. 2004 May;89(5):2222-7.PMID: 15126545 [PubMed - indexed for MEDLINE]Related articlesFree article

    44.

    The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes.

    Greenbaum C, Seidel K, Pihoker C.

    Diabetes Care. 2004 May;27(5):1202-4. No abstract available. PMID: 15111546 [PubMed - indexed for MEDLINE]Related articlesFree article

    45.

    Future intervention trials in type 1 diabetes.

    Wilkin T, Ludvigsson J, Greenbaum C, Palmer J, Becker D, Bruining J.

    Diabetes Care. 2004 Apr;27(4):996-7. Review. No abstract available. PMID: 15047664 [PubMed - indexed for MEDLINE]Related articlesFree article

    46.

    Systematic screening of potential beta-cell imaging agents.

    Sweet IR, Cook DL, Lernmark A, Greenbaum CJ, Wallen AR, Marcum ES, Stekhova SA, Krohn KA.

    Biochem Biophys Res Commun. 2004 Feb 20;314(4):976-83.PMID: 14751228 [PubMed - indexed for MEDLINE]Related articles

    47.

    C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

    Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW.

    Diabetes. 2004 Jan;53(1):250-64. Erratum in: Diabetes. 2004 Jul;53(7):1934. PMID: 14693724 [PubMed - indexed for MEDLINE]Related articlesFree article

    48.

    Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.

    Greenbaum CJ, Harrison LC; Immunology of Diabetes Society.

    Diabetes. 2003 May;52(5):1059-65. No abstract available. Erratum in: Diabetes. 2003 Oct;52(10):2643. PMID: 12716733 [PubMed - indexed for MEDLINE]Related articlesFree article

    49.

    Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation.

    Plesner A, Greenbaum CJ, Gaur LK, Ernst RK, Lernmark A.

    Scand J Immunol. 2002 Nov;56(5):522-9.PMID: 12410803 [PubMed - indexed for MEDLINE]Related articles

    50.

    Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials.

    Greenbaum CJ.

    Clin Immunol. 2002 Aug;104(2):97-104. Review.PMID: 12165270 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data

    Search details

    » See more...